Increased GLS1 expression in a variety of human cancer types was associated with significantly decreased patient survival, which suggests its function as a potential prognostic biomarker for many human cancers, including hepatocellular carcinoma (HCC), ovarian cancer, osteosarcoma, colorectal cancer (CRC) and breast cancer (64, 81–85). This evidence concerns the gene GLS and colorectal carcinoma.